anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients receive modified vaccinia virus ankara vaccine expressing p53 SC on day 15 and gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. Treatment repeats every 21 days for up to 3 courses in the absence of disease progression or unacceptable toxicity. Patients then continue to receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8 every 21 days in the absence of disease progression or unacceptable toxicity.
Participants will receive Adebrelimab intravenously in combination with carboplatin /Cisplatin and etoposide during the induction phase (2 Cycles ). Thereafter, participants will receive concurrent chemoradiotherapy(thoracic radiation therapy and SBRT for metastases,combination with carboplatin /Cisplatin and etoposide for 1-2 Cycles).Then participants will receive Adebrelimab combination with carboplatin /Cisplatin and etoposide for 1-2 Cycles,followed by Adebrelimab maintenance until persistent radiographic PD, intolerable toxicity or withdrawal of consent during the maintenance phase.
Group 2 will receive best systemic therapy (BST) in addition to surgery to remove prostate or radiation therapy to the prostate. Treating physician will decide if surgery or radiation therapy is the best choice. Questionnaire completion at 60 days, 12 weeks, and at end of treatment visit. It should take about 15 minutes to complete. Every 6 months after end-of-treatment visit, patient contacted by phone or e-mail and asked questions about how they are feeling. Each phone call should last about 5 minutes.
Patients were randomly assigned into 2 groups as popliteal sciatic nerve block (Group PSB), popliteal sciatic nerve + adductor canal block (Group PSB + ACB). In this study, 52 patients scheduled for hallux valgus correction operations, in the American Society of Anesthesiologists I-III groups, between the ages of 18-80, were enrolled. Study was planned as a prospective, randomized and controlled trial. All patients were perfomed PSB with 10 ml 0.5% bupivacaine and 10 ml 2% prilocaine in the prone position, using ultrasonography and nerve stimulator. 10 ml of 0.5% bupivacaine and 10 ml of 2% prilocaine were administered to the patients in the ACB + PSB group in the supine position, in addition to PSB. Patients with coagulopathy, infection at the region site of regional blockade, allergy of local anesthetic drugs, peripheral neuropathy and neurogenic disorders affecting the lower extremities, peripheral artery disease, mental retardation and those who did not give consent to study were excluded. All patients were sedated with 1-2 mg midazolam and 50 µg fentanyl. After the blocks were performed , sensory -motor block onset time, surgery-tourniquet time, tourniquet pain, motor block time, pain onset time, first analgesic administration time (NPRS≥4) and analgesic administered were recorded. Anesthesiologists evaluating these data were blinded to group distribution .
Within each of the 7 regions, this group is comprised of practices that were matched to the treatment practices on a wide range of baseline characteristics of the practices (including their service utilization patterns) and their patients. Comparison practices were selected from a pool of practices including those that applied to participate but were not selected, and practices serving nearby external comparison areas.
Oral SUBA-itraconazole 65 mg 2 capsules BD for 4 months. Oral itraconazole will be given twice daily (9 am and 9 pm) spaced one hour with meals. We will perform therapeutic drug monitoring for itraconazole at two weeks and two months. We will increase the itraconazole dose to a maximum of 390 mg/day (six 65 mg capsules) in those with trough itraconazole levels \<0.5 µg/mL.
The present application relates to a method of selecting surgical implants and related devices. Methods may be provided to identify a medical implant from a plurality of medical implants for fixation to an anatomical surface. A dimensional parameter for each of the plurality of medical implants may be provided, and a dimensional parameter corresponding to the anatomical surface may be provided. The size parameter of each of the plurality of medical implants may be compared to the size parameter corresponding to the anatomical surface, and one medical implant may be selected from the plurality of medical implants based on the size parameter of each of the plurality of medical implants corresponding to the anatomical surface. The identification of a medical implant selected from a plurality of medical implants may be provided through a user interface. Related apparatus and computer program products are also discussed.
The invention relates to Vitamin D2 solid dispersion coated tablet and the preparation method thereof, belonging to pharmaceutical preparation technical field. The tablet contains Vitamin D2 and pharmaceutical excipient, with Vitamin D2 as the active component. Every ten thousand tablets contain 0.3125g of Vitamin D2, 100g of PEG-6000, 2500g of starch, 2250g of phosphoric acid calcium hydrogen, 75ml of alcohol, 100g of magnesium stearate and 50g of talc. The invention has a simple preparation method, according to which Vitamin D2 is coated to produce tablets. The Vitamin D2 tablets prepared in the method has obvious treating effects and can be taken orally. The toxicity is low and the bioavailability is greatly enhanced. Besides, the tablet has the functions of sustaining, targeting, energy provision for human organism, etc.
The present invention relates to biomarkers of use for treating Trap-2 expressing cancer with an anti-Trop-2 ADC comprising an anti-Trop-2 antibody conjugated to an inhibitor of topoisomerase I, preferably SN-38 or DxD. The anti-Trop-2 ADC may be administered as a monotherapy or as a combination therapy with one or more anti-cancer agents, such as DDR inhibitors. Therapy with the ADC alone or in combination with other anti-cancer agents can reduce solid tumors in size, reduce or eliminate metastases and is effective to treat cancers resistant to standard therapies. Preferably, the combination therapy has an additive effect on inhibiting tumor growth. Most preferably, the combination therapy has a synergistic effect on inhibiting tumor growth. In specific embodiments, the biomarker may relate to a gene selected from the group consisting of
Patients receive temozolomide PO QD on days 1-5. Treatment repeats every 28 days for up to 13 cycles in the absence of disease progression or unacceptable toxicity. Patients undergo CT with contrast or MRI throughout the study and undergo mandatory collection of blood samples prior to treatment. Patients may optionally undergo collection of blood samples at the time of progression.
Efficacy:

The efficacy of TRIKAFTA in patients with CF aged 12 years and older was evaluated in two double-blind, controlled trials (Trials 1 and 2).

Trial 1 was a 24-week, randomized, double-blind, placebo-controlled study in patients who had an F508del mutation on one allele and a mutation on the second allele that results in either no CFTR protein or a CFTR protein that is not responsive to ivacaftor and tezacaftor/ivacaftor. An interim analysis was planned when at least 140 patients completed Week 4 and at least 100 patients completed Week 12. 

Trial 2 was a 4-week, randomized, double-blind, active-controlled study in patients who are homozygous for the F508del mutation. Patients received tezacaftor 100 mg qd/ivacaftor 150 mg q12h during a 4-week, open-label run-in period and were then randomized and dosed to receive TRIKAFTA or tezacaftor 100 mg qd/ivacaftor 150 mg q12h during a 4-week, double-blind treatment period.

Patients in Trials 1 and 2 had a confirmed diagnosis of CF and at least one F508del mutation. Patients discontinued any previous CFTR modulator therapies, but continued on their other standard-of-care CF therapies (e.g., bronchodilators, inhaled antibiotics, dornase alfa and hypertonic saline). Patients had a ppFEV1 at screening between 40-90%. Patients with a history of colonization with organisms associated with a more rapid decline in pulmonary status, including but not limited to Burkholderia cenocepacia, Burkholderia dolosa, or Mycobacterium abscessus, or who had an abnormal liver function test at screening (ALT, AST, ALP, or GGT ≥3 × ULN, or total bilirubin ≥2 × ULN), were excluded from the trials. Patients in Trials 1 and 2 were eligible to roll over into a 96-week, open-label extension study.
The invention is a prepackaged therapeutic meal for administration to a patient having at least one diet-responsive condition. The meal includes a plurality of separate meal components. At least one of the meal components contains a predetermined level of nutritional enhancement. The nutritionally enhanced meal component may be selected from the group consisting of meats, baked goods, sauces, starch sources, cereals, soups, desserts, and fruit juice beverages. In particular, the component supplies dietary fiber in the range of up to about grams; vitamins and minerals at a range of at least about 5 to 35 % USRDA;  sodium in an amount less than about 2400 mg; potassium in an amount less than about 3500 mg; protein, such that up to about 30 % of caloric intake is derived from protein; and fat, such that up to about 20 % of caloric intake is derived from fat. Consumption of a daily diet including at least three of the meals supplies the patient with a desired total daily caloric content, improved quality of life, and sufficient nutritional enhancement to facilitate management of the diet-responsive condition.
Current methods used to investigate emotional inference and conflict resolution knowledge are limited in their suitability for use with children with language disorders due to a reliance on language processing. This is problematic, as nearly 8% of the population are estimated to have developmental language disorder (DLD). In this paper, we present 'Zoti's Social Toolkit', a set of animated scenarios that can be used to assess emotion inferencing and conflict resolution knowledge. All animated scenarios contain interpersonal situations centred around a gender-neutral alien named Zoti. Four studies investigated the face and construct validity of the stimuli. The final stimulus set can be used with children, who may or may not have language difficulties and is openly available for use in research.
PURPOSE:To provide a hair cosmetic having excellent applicability and containing a cationic surfactant and a substance having a specific boiling point. CONSTITUTION:The objective cosmetic can be prepared according to conventional cosmetic-preparation process by compounding (A) 0.05-20wt.% of a cationic surfactant, (B) 0.1-95wt.% of a substance having a boiling point of 0-50 deg.C under normal pressure (e.g. methane-series hydrocarbon) and, as necessary, (C) at least one kind of component selected from water-soluble polymer compounds, nonionic surfactants and alkanolamide and properly compounding arbitrary components such as emulsion stabilizer, higher alcohol, thickener, perfumery, oil and disinfectant. It can be used as hair rinse, hair conditioner, hair treatment, hair pack, hair spray, styling mousse, hair liquid, etc. It imparts hair with highly voluminous feeling and slimy feeling. It can be smoothly rinsed and gives dried hair having excellent combing easiness, smoothness and moistness.
Stage 1 of this study has completed. Stage 1 was an open-label, Simon two stage, Phase 2 study to determine the efficacy and safety of two different dose schedules of RO7490677 in participants with PMF and post ET/PV MF. There were two treatment cohorts, each assigned to one of two dose schedules receiving either single-agent RO7490677 or RO7490677 in combination with ruxolitinib. Participants were assigned to a weekly or every four week dosing schedule by the investigator.

Stage 2 is a randomized, double-blind Phase 2 study to determine the efficacy and safety of three different doses of RO7490677 in participants with PMF and post ET/PV MF. Participants will be randomized to one of three doses: 0.3 mg/kg, 3.0 mg/kg or 10 mg/kg of RO7490677. This is the second stage of an adaptive design study as defined in FDA Draft Guidance for Industry: Adaptive Design Clinical Trials for Drugs and Biologics, February 2010. Modifications to dose levels, schedule, and regimen have been made in Stage 2 based on data from Stage 1.
PURPOSE:To simply measure isolated type thyroxin in blood, by labelling a bond of thyroxin and polypeptide with <125>I or the like to perform a radiation immunoassay using the labelled antigen obtained. CONSTITUTION:A T4-polypeptide bond is obtained from thyroxin (T4) and polypeptide by a glutaric aldehyde method. The bond thus obtained is inactive to a thyroxin-bonded globulin (TBG) and albumin but makes a bond reaction with T4. Then, the bond is labelled with, for example, <125>I or the like to make a labelled antigen, which is used to measure thyroxin T4 in blood by a radiation immunoassay method. Here, for example, a bond of thyroxin and sex gland stimulating hormone labelled with <125>I is used. Thus, the use of the labelled antigen enables sensitive measurement of isolated type thyroxin without being affected by coexisting components in blood, TBG and the like this method is highly effective for the decision on the function of a thyroid gland.
This group has patients diagnosed with breast cancer who have chosen not to have bilateral mastectomy (e.g. they may have unilateral mastectomy, lumpectomy, radiation, etc. but not bilateral mastectomy). Patients complete questionnaires over 1 hour, undergo fMRI related tasks over 2-2.5 hours, and blood/saliva sample collection upon awakening, 30 minutes after awakening, and at 9 pm in the evening for 3 consecutive days.
Body dissatisfaction is one of the most robust risk factors for developing unhealthy behaviors, low self-esteem, and contributes to anxiety and depression in adolescence. Despite evidence that body dissatisfaction can emerge during the elementary school years, the majority of body confidence programs are for girls over the age of 15. There is very little to no research on interventions for elementary school children. The Body Project is an empirically supported body confidence prevention program for high school girls with over 100 articles to support its efficacy, effectiveness and theoretical model; it is the only body confidence program for youth to acquire the Blueprints Certification. Together with two 4th and 5th grade teachers, the investigators have adapted the Body Project curriculum for youth between the ages of 9 to 11 years old (i.e., 4th and 5th graders). The curriculum is called Amazing Me and will be implemented in classrooms by teachers. The curriculum was developed meeting several competencies for national health and wellness standards for elementary students. The aim of the current study is to conduct a national randomized control trial of the curriculum 100 classrooms with 4th and 5th graders.

The primary aim of the current study is to deliver the Amazing Me intervention and assess its efficacy. It is hypothesized that compared to controls, children that undergo the body confidence curriculum will report higher body satisfaction and body esteem scores, overall greater self-esteem, and will report less engagement in appearance comparisons.
An isolated nucleic acid encoding the Helicobacter pylori recombinase is provided. Also provided is an isolated nucleic acid that hybridizes with the recombinase-encoding nucleic acid under stringent conditions and has at least 70% complementarity with the segment of the nucleic acid of SEQ ID NO:1 to which it hybridizes. Also provided is a mutant strain of H. pylori that does not express a functional recombinase (recA- mutant). An isolated nucleic acid encoding the Helicobacter pylori enolase is provided. Also provided is an isolated nucleic acid that hybridizes with the nucleic acid that encodes a H. pylori recombinase under stringent conditions and has at least 70% complementarity with the segment of the nucleic acid of SEQ ID NO:9 to which it hybridizes. Also provided is a mutant strain of H. pylori that does not express a functional enolase (eno- mutant). A method is provided for immunizing a subject against infection by H. pylori by administering to the subject an immunogenic amount of mutant H. pylori in a carrier for the mutant.
The present invention provides methods for diagnosing or identifying susceptibility of a subject to an anxiety or mood disorder. One method involves testing a sample obtained from the subject for the presence of a polymorphism in Intron 10 of the SLC1A1 gene. The presence of allele G or allele A of the A/G polymorphism rs301434 indicates that the patient is susceptible to an anxiety disorder. An alternate method involves testing a sample obtained from the subject for the presence of a polymorphism in the 3' untranslated region of the SLC1A1 gene. The presence of allele C of C/G polymorphism rs3087879 indicates that the patient is susceptible to an anxiety disorder. Furthermore, a method is provided that involves testing a sample obtained from the subject for the presence of a haplotype in the SLC1A1 gene, wherein the combined presence allele G of the A/G polymorphism rs301434 and allele C of C/G polymorphism rs3087879 indicates that the patient is susceptible to a mood disorder.
PURPOSE: A composition containing deep sea water is provided to reduce neutral fat, cholesterol, phospholipide, and hydroxyl radical and to prevent and treat obesity or hyperlipidemia. CONSTITUTION: A pharmaceutical composition for preventing and treating obesity or hyperlipidemia and arteriosclerotic vascular diseases contains deep sea water as an active ingredient. The deep sea water is collected under 300-1300m from East sea. The arteriosclerotic vascular diseases include artery scleroma, cardiac insufficiency, hypertensive heart disease, arrhythmia, congenital heart disease, myocardial infarction, angina, stroke, or peripheral vascular disease. A health food for preventing and treating obesity and arteriosclerotic vascular diseases contains the deep sea water as an active ingredient. The health food is powder, granule, tablet, capsule, or beverage.
OBJECTIVE: The present study was performed to evaluate the effect of ultrasound-guided erector spinae plane block (ESPB) on pain after laparoscopic transabdominal preperitoneal (TAPP) repair. Therefore, improved postoperative pain management is crucial for enhancing the overall patient experience and recovery.
METHODS: This prospective, double-blind, randomized controlled trial enrolled 40 male patients with a unilateral inguinal hernia at Xi'an Aerospace General Hospital from November 1, 2020, to February 1, 2021. Participants were assigned through a random number table at a 1:1 ratio to receive either ESPB with 20 ml 0.5% ropivacaine in the experimental group (Group E) or ESPB with 20 ml normal saline in the control group (Group C), with 20 cases in each group. The primary outcome was assessed using visual analogue scale (VAS) scores for exercise pain at 2h, 6h, 12h, 18h, and 24h postoperatively. Secondary outcomes included time lapses before patient-controlled intravenous analgesia (PCIA) use, intraoperative remifentanil usage, additional sufentanil, postoperative nalbuphine consumption, analgesic remedies at 24h postoperatively, and incidence of postoperative adverse events.
RESULTS: Group E provided more pain mitigation for patients than Group C, as evidenced by the significantly lower VAS scores during exercise pain at 2h (Group C: 1.95±1.19; Group E:4.00±1.38), 6h (Group C: 2.00±1.12; Group E:3.90±1.37), and 12h (Group C: 2.05±1.05; Group E:3.55±1.36) postoperatively (P < .05), and the pain mitigation for Group C was significant only at 18h and 24h postoperatively compared to at 2h postoperatively (P < .05). Group E resulted in significantly reduced intraoperative use of remifentanil and, additional sufentanil and postoperative nalbuphine consumption versus Group C (P < .05). Group E exhibited a better pain tolerance than Group C, as demonstrated by the longer time lapse before the use of PCIA (RR value=5.709, t=8.446, P < .05). Group C required more analgesic remedies within 24 h after surgery than Group E (P < .05). Group E did not increase the risk of postoperative adverse events, given the absence of statistical significance in the intergroup comparison (P > .05).
CONCLUSION: Ultrasound-guided ESPB demonstrates notable benefits by decreasing intraoperative and postoperative anesthetic drug requirements, enhancing pain management, and elevating postoperative comfort and quality of life for patients. While acknowledging the study's limitations, it is crucial to highlight the potential clinical implications of these findings. The incorporation of ESPB with ropivacaine into postoperative pain management protocols could represent a significant advancement in clinical practice. The observed improvements in pain management and reduced reliance on anesthetic drugs may lead to more tailored and efficient postoperative care, potentially enhancing patient recovery experiences. Further research and practical implementation studies are warranted to fully elucidate the specific impact and optimal integration of ESPB with ropivacaine within broader clinical settings.
Open-label access; The initial dose of Remodulin for this study will be the same as each subject's final dose in study CVT-CV-003. Dose modification will be based according to clinical response and tolerability.
Pravastatin sodium is highly effective in reducing Total-C, LDL-C, and TG in patients with heterozygous familial, presumed familial combined, and non-familial (non-FH) forms of primary hypercholesterolemia, and mixed dyslipidemia. A therapeutic response is seen within 1 week, and the maximum response usually is achieved within 4 weeks. This response is maintained during extended periods of therapy. In addition, pravastatin sodium is effective in reducing the risk of acute coronary events in hypercholesterolemic patients with and without previous MI.

A single daily dose is as effective as the same total daily dose given twice a day. In multicenter, double-blind, placebo-controlled studies of patients with primary hypercholesterolemia, treatment with pravastatin in daily doses ranging from 10 to 40 mg consistently and significantly decreased Total-C, LDL-C, TG, and Total-C/HDL-C and LDL-C/HDL-C ratios (see Table 4).

In a pooled analysis of 2 multicenter, double-blind, placebo-controlled studies of patients with primary hypercholesterolemia, treatment with pravastatin at a daily dose of 80 mg (N=277) significantly decreased Total-C, LDL-C, and TG. The 25th and 75th percentile changes from baseline in LDL-C for pravastatin 80 mg were −43% and −30%. The efficacy results of the individual studies were consistent with the pooled data (see Table 4).

Treatment with pravastatin sodium modestly decreased VLDL-C and pravastatin sodium across all doses produced variable increases in HDL-C (see Table 4).

In another clinical trial, patients treated with pravastatin in combination with cholestyramine (70% of patients were taking cholestyramine 20 or 24 g per day) had reductions equal to or greater than 50% in LDL-C. Furthermore, pravastatin attenuated cholestyramine-induced increases in TG levels (which are themselves of uncertain clinical significance).